Disclosed are 2-(imidazo[1,2-a]pyridin-2-yl)pyrrolidine derivatives as represented by the general formula (I), wherein: X1 and X2 are each independently O or S Y is CH2 Z is H, alkyl, a carbocycle or a heterocycle which may be substituted Q is H, halogen, hydroxyl, carboxyl, amino, nitro, cyano, alkyl, a carbocycle or a heterocycle wherein said alkyl, carbocycle and heterocycle may be substituted R1, R3, R4, R5, R6 and R6 are each hydrogen R2 is morpholino or cyclohexyl R3 and R4 are methyl R7 is H, cyano, hydroxyl, mercapto, halogen, nitro, carboxyl, amidino, guanidino, alkyl, a carbocycle, a heterocycle or -U-V R8 is H, alkyl, a carbocycle or a heterocycle wherein one or more CH2 or CH groups of said alkyl is optionally replaced with -O-, -S-, -S(O)-, S(O)2, or -C(O)- and said alkyl, carbocycle and heterocycle is optionally substituted and m is 0 to 4 or a salt or stereoisomer thereof. Representative compounds include those where the 2-(imidazo[1,2-a]pyridin-2-yl)pyrrolidine moiety is substituted on the 1-position with N-methyl-L-alanine-L-cyclohexylglycine or N-methyl-L-alanine-L-morpholin-4-ylglycine. Further disclosed is a pharmaceutical composition which comprises a compound as defined above and a carrier, diluent or excipient for the treatment of cancer.
